Esketamine for treatment resistant depression
The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Introduction : Treatment Resistant Depression (TRD) is a common and burdensome condition with poor outcomes and few treatment options. Esketamine is the S-enantiomer of ketamine and has recently been FDA approved in the United States for treating depression that has failed to respond to trials of two or more antidepressants. Areas covered : This review will briefly discuss current treatment options for TRD, then review esketamine. Relevant literature was identified through online database searches, and clinical trial data were provided by Janssen Pharmaceuticals. Pharmacology, including kinetics and dynamics, is discussed, then clinical data regarding efficacy and safety for esketamine from Phase 2-3 trials are reviewed. Expert opinion : In the expert opinion, the authors discuss multiple factors including patient, physician, and social factors that will influence the use of esketamine. While the efficacy of esketamine compared to off-label use of racemic ketamine remains unclear, both esketamine's approval for use in TRD and longer-term safety data may position it preferentially above racemic ketamine, although factors such as cost and monitoring requirements may limit its use. While questions remain regarding duration and frequency of treatment, as well as addictive potential, esketamine is a novel treatment option offering new hope for TRD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“esketamine has demonstrated the ability to produce significant symptom relief rapidly, with substantial reductions in depressive symptoms [13,14].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [14]
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“chiatric and medical comorbidities [3].”
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“reported on the first randomized controlled clinical trial of IV ketamine on nine depressed patients after a two-week medication washout period [19].”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Grand challenges in global mental health
Collins, P. Y., Patel, V., Joestl, S. S., March, D., Insel, T. R., Daar, A. S., Bordin, I. A., Costello, E. J., Durkin, M., Fairburn, C., et al. (2011) · Nature · doi:10.1038/475027a · Cited by 2,043
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · cited 1×
“The Canadian Mood and Anxiety Disorder Network (CANMAT) has placed IV ketamine as a third line adjunctive treatment for depression in its 2018 Bipolar Disorder Treatment guidelines [93], but the 2016 Depression treatment guidelines still list ketamine as an ‘experimental’ treatment [6], which has limited its use.”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“In the disinhibition hypothesis, subanaesthetic doses of ketamine have a preferential affinity for NMDA receptors on gamma-aminobutyric acid (GABA)-secreting inhibitory interneurons, resulting in pyramidal cell disinhibition and an increase in glutamate release and extracellular glutamate concentration [46].”
BackgroundGlobal burden of depressive disorders in the year 2000
Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. L. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.5.386 · Cited by 1,735
(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 1×
“The active metabolite of ketamine (2R,6R)-hydroxynorketamine (HNK) has been reported to exert antidepressant-like effects without side-effect behaviors in mice and apparently targets receptor binding sites other than NMDA receptors that currently remain unknown [50].”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399 · cited 1×
“teric phencyclidine (PCP) site within the ionotropic channel pore [16,17].”
BackgroundDevelopment of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 1×
“In one review of several substances of abuse, ketamine was identified as having a relatively high ‘harm score’, similar to substances such as alcohol and benzodiazepines [90].”
BackgroundKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · cited 2×
“Voltage-gated sodium channels and L and T-type voltage-dependent calcium channels have also been suggested to be involved in the therapeutic benefit of ketamine [56]; for a review see [40].”
BackgroundThe psychology of suicidal behaviour
O'Connor, R. C., & Nock, M. K. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70222-6 · Cited by 1,193
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181 · cited 1×
“The Canadian Mood and Anxiety Disorder Network (CANMAT) has placed IV ketamine as a third line adjunctive treatment for depression in its 2018 Bipolar Disorder Treatment guidelines [93], but the 2016 Depression treatment guidelines still list ketamine as an ‘experimental’ treatment [6], which has limited its use.”
BackgroundKetamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036 · cited 1×
“Voltage-gated sodium channels and L and T-type voltage-dependent calcium channels have also been suggested to be involved in the therapeutic benefit of ketamine [56]; for a review see [40].”
BackgroundPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 3×
“to a statistically significant positive trial [66,69].”
BackgroundTreatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“While response rate has been reported as 40–90% in patients with TRD [21] and 44% in patients with ultra-resistant depression (URD) [23], the time to depressive relapse averages 18 days after the last infusion [20].”
BackgroundCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711 · cited 1×
“Interestingly, it has been suggested that ketamine’s antidepressant effect, but not its dissociative effect, may depend on activation of the opioid system [53].”
BackgroundCanuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Berlim, M. T., van den Eynde, F., Tovar-Perdomo, S., & Daskalakis, Z. J. (2014) · Psychological Medicine · doi:10.1017/s0033291713000512 · Cited by 620
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576 · cited 2×
“It would be wise for any clinician prescribing esketamine to also review and implement the suggestions detailed there [92].”
BackgroundSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558 · cited 2×
“remained stable or improved after treatment for up to 1 year [76,77].”
BackgroundAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519 · cited 1×
“Although it is known that naltrexone blocks the antidepressant effects of ketamine, it is unclear whether this is due to binding to mu opioid receptors or ketamine-mediated release of endogenous opioids [54], which may be important in considering addictive potential.”
BackgroundA Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 3×
“ciation and psychotic symptoms, but did not comment on the frequency of occurrence [24], and a subsequent IN ketamine”
BackgroundResultTreatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421 · cited 1×
“respond and those who have tried adjunctive strategies [4].”
BackgroundCOMPARATIVE PHARMACOLOGY OF THE KETAMINE ISOMERS
WHITE, P. F., SCHÜTTLER, J., SHAFER, A., STANSKI, D. R., HORAI, Y., & TREVOR, A. J. (1985) · British Journal of Anaesthesia · doi:10.1093/bja/57.2.197 · Cited by 415
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385 · cited 1×
“Mean absolute bioavailability of IN esketamine is equal to that of ketamine [52].”
BackgroundKetamine-Associated Ulcerative Cystitis: A New Clinical Entity
Shahani, R., Streutker, C., Dickson, B., & Stewart, R. J. (2007) · Urology · doi:10.1016/j.urology.2007.01.038 · Cited by 373
The destruction of the lower urinary tract by ketamine abuse: a new syndrome?
Chu, P. S., Ma, W., Wong, S. C., Chu, R. W., Cheng, C., Wong, S., Tse, J. M., Lau, F., Yiu, M., & Man, C. (2008) · BJU International · doi:10.1111/j.1464-410x.2008.07920.x · Cited by 368
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Berlim, M. T., Van den Eynde, F., & Jeff Daskalakis, Z. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.237 · Cited by 298
Lam, R. W., McIntosh, D., Wang, J., Enns, M. W., Kolivakis, T., Michalak, E. E., Sareen, J., Song, W.-Y., Kennedy, S. H., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659416 · Cited by 288
Ketamine use in current clinical practice
Gao, M., Rejaei, D., & Liu, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.5 · Cited by 286
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279 · cited 18×
“While response rate has been reported as 40–90% in patients with TRD [21] and 44% in patients with ultra-resistant depression (URD) [23], the time to depressive relapse averages 18 days after the last infusion [20].”
BackgroundInfluentialAntidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain
Mathisen, L. C., Skjelbred, P., Skoglund, L. A., & Øye, I. (1995) · Pain · doi:10.1016/0304-3959(94)00170-j · Cited by 245
The role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
Wan, L.-B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., Foulkes, A., Mathew, S. J., Charney, D. S., & Murrough, J. W. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08852 · Cited by 231 · cited 1×
“Comparatively, 24% of patients reported feeling ‘strange or unreal’ within 120 min of racemic IV ketamine infusion [78].”
BackgroundZimmerman, M., Posternak, M. A., & Chelminski, I. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.03.007 · Cited by 229 · cited 1×
“088 for the 84 mg arm), but results were stated to be clinically significant based on the change seen in subjects and not compared to placebo, which is a difficult assertion without statistical significance [67,68].”
BackgroundYanagihara, Y., Ohtani, M., Kariya, S., Uchino, K., Hiraishi, T., Ashizawa, N., Aoyama, T., Yamamura, Y., Yamada, Y., & Iga, T. (2003) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.336 · Cited by 219 · cited 2×
“higher than after administration by oral tablet, sublingual tablet or suppository (20%, 30%, and 30%, respectively) [57].”
BackgroundKETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS
Abdallah, C. G., Adams, T. G., Kelmendi, B., Esterlis, I., Sanacora, G., & Krystal, J. H. (2016) · Depression and Anxiety · doi:10.1002/da.22501 · Cited by 206 · cited 1×
“produce rapid antidepressant and anti-suicidal efficacy that is sustained well beyond its half-life [27].”
BackgroundVagus nerve stimulation for depression: efficacy and safety in a European study
Schlaepfer, T. E., Frick, C., Zobel, A., Maier, W., Heuser, I., Bajbouj, M., O'Keane, V., Corcoran, C., Adolfsson, R., Trimble, M., et al. (2008) · Psychological Medicine · doi:10.1017/s0033291707001924 · Cited by 205
A REVIEW OF KETAMINE ABUSE AND DIVERSION: Review: Ketamine
Sassano-Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016) · Depression and Anxiety · doi:10.1002/da.22536 · Cited by 204
Miller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200 · cited 2×
“mTOR synaptic plasticity, also in a protein-synthesis dependent manner [18].”
BackgroundDescriptive Epidemiology of Major Depressive Disorder in Canada in 2012
Patten, S. B., Williams, J. V. A., Lavorato, D. H., Wang, J. L., McDonald, K., & Bulloch, A. G. M. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000106 · Cited by 190
Pfenninger, E. G., Durieux, M. E., & Himmelseher, S. (2002) · Anesthesiology · doi:10.1097/00000542-200202000-00022 · Cited by 189
Chang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176 · cited 1×
“that S-norketamine may also be a useful antidepressant with fewer adverse effects than esketamine (see [43] for review).”
BackgroundWilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173
Berlim, M. T., McGirr, A., den Eynde, F. V., Fleck, M. P., & Giacobbe, P. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.016 · Cited by 149
Ihmsen, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.119722 · Cited by 136
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132 · cited 3×
“However, based on animal experiments, Zhang and Hashimoto [55] suggested that the opioid system may not play a role in ketamine’s antidepressant effects.”
BackgroundElectroconvulsive therapy vs. paroxetine in treatment‐resistant depression — a randomized study
Folkerts, H. W., Michael, N., Tölle, R., Schonauer, K., Mücke, S., & Schulze‐Mönking, H. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09926.x · Cited by 130 · cited 1×
“While efficacy is promising at 71% [7], use of ECT is limited by the need for general anesthesia, hospital resources, the potential for sideeffects and stigma [7,8].”
BackgroundMorgan, C. J. A., Riccelli, M., Heriot-Maitland, C., & Curran, H. V. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.03.006 · Cited by 129 · cited 1×
“noted in chronic ketamine abusers [86].”
Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0692-7 · Cited by 127
Shiroma, P. R., Albott, C. S., Johns, B., Thuras, P., Wels, J., & Lim, K. O. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714001011 · Cited by 126 · cited 1×
“of depressive symptoms with treatment [87].”
Lodge, D., Anis, N. A., & Burton, N. R. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90330-5 · Cited by 126 · cited 1×
“teric phencyclidine (PCP) site within the ionotropic channel pore [16,17].”
BackgroundKetamine enantiomers in the rapid and sustained antidepressant effects
Muller, J., Pentyala, S., Dilger, J., & Pentyala, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316631267 · Cited by 122 · cited 1×
“There is considerable disagreement in the literature about the degree of adverse effects such as dissociation, psychoses, and cognitive effects with esketamine [29–45]and readers are referred especially to two comprehensive review articles on this matter [30,40]; it should be remembered that some of the studies report…”
BackgroundFanta, S., Kinnunen, M., Backman, J. T., & Kalso, E. A. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1826-y · Cited by 122 · cited 1×
“extensive hepatic first-pass metabolism [58,59].”
Senova, S., Cotovio, G., Pascual-Leone, A., & Oliveira-Maia, A. J. (2019) · Brain Stimulation · doi:10.1016/j.brs.2018.10.001 · Cited by 119
Joyce, P. R., Mulder, R. T., Luty, S. E., Sullivan, P., McKenzie, J. M., Abbott, R., & Stevens, I. (2002) · Australian and New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2001.01026.x · Cited by 118 · cited 6×
“Major depressive disorder (MDD) is a common disease with a lifetime prevalence of 9.9% [1].”
BackgroundInfluentialCao, X., Deng, C., Su, X., & Guo, Y. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00413 · Cited by 118
Domany, Y., Bleich-Cohen, M., Tarrasch, R., Meidan, R., Litvak-Lazar, O., Stoppleman, N., Schreiber, S., Bloch, M., Hendler, T., & Sharon, H. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.196 · Cited by 114
Martin, J. L. R., & Martín-Sánchez, E. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.07.006 · Cited by 102
Portmann, S., Kwan, H. Y., Theurillat, R., Schmitz, A., Mevissen, M., & Thormann, W. (2010) · Journal of Chromatography A · doi:10.1016/j.chroma.2010.06.028 · Cited by 101 · cited 1×
“CYP-dependent pathways to metabolites such as S-5-hydroxynorketamine (HNK) and S-5,6-dehydronorketamine (DHNK) which are further metabolized by glucuronidation [61].”
BackgroundA Word to the Wise About Intranasal Esketamine
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19040423 · Cited by 96 · cited 2×
“Due to lack of consistency, the FDA report on esketamine indicates it is difficult to attribute suicides to the drug, however a recent commentary on esketamine [77] aptly points out that high relapse rates have been demonstrated on discontinuation of esketamine, and cautions that protracted withdrawal from the drug, r…”
BackgroundDevelopment of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain
Chong, C., Schug, S. A., Page‐Sharp, M., Jenkins, B., & Ilett, K. F. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00004 · Cited by 93 · cited 1×
“extensive hepatic first-pass metabolism [58,59].”
Yang, C., Han, M., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.03.034 · Cited by 91
Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., Alonzo, A., Rodgers, A., Mitchell, P. B., & Loo, C. K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118760660 · Cited by 85 · cited 1×
“Patients in this study experienced extreme side effects that prevented several patients from continuing to self-administer the nasal sprays of the drug [25].”
BackgroundKetamine for Depression, 3: Does Chirality Matter?: (Clinical and Practical Psychopharmacology)
Andrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f11681 · Cited by 78 · cited 1×
“may reside primarily in one enantiomer, and the two enantiomers may influence each other’s pharmacokinetics [28,29].”
BackgroundGaynes, B. N., Dusetzina, S. B., Ellis, A. R., Hansen, R. A., Farley, J. F., Miller, W. C., & Stürmer, T. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f705d · Cited by 78
Assessment Scales in Depression, Mania and Anxiety
Lam, R. W. M., Michalak, E. E., & Swinson, R. P. (2004) · Medical Entomology and Zoology · Cited by 75
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P.-M. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 74
Morrison, R. L., Fedgchin, M., Singh, J., Van Gerven, J., Zuiker, R., Lim, K. S., van der Ark, P., Wajs, E., Xi, L., Zannikos, P., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4828-5 · Cited by 72
Lack of Opioid System in the Antidepressant Actions of Ketamine
Zhang, K., & Hashimoto, K. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.11.006 · Cited by 71 · cited 2×
“However, based on animal experiments, Zhang and Hashimoto [55] suggested that the opioid system may not play a role in ketamine’s antidepressant effects.”
BackgroundThomas, R. K., Baker, G., Lind, J., & Dursun, S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118793104 · Cited by 69 · cited 7×
“URD has been defined as a failure of over five antidepressants ± ECT [22].”
BackgroundResultInfluentialSelf-citationKetamine’s antidepressant action: beyond NMDA receptor inhibition
Hashimoto, K. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1238899 · Cited by 68
Baker, G. B., & Prior, T. I. (2002) · Annals of Medicine · doi:10.1080/078538902321117742 · Cited by 68 · cited 1×
“may reside primarily in one enantiomer, and the two enantiomers may influence each other’s pharmacokinetics [28,29].”
BackgroundSelf-citationTian, Z., Dong, C., Fujita, A., Fujita, Y., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.07.003 · Cited by 62
Correia-Melo, F. S., Leal, G. C., Carvalho, M. S., Jesus-Nunes, A. P., Ferreira, C. B. N., Vieira, F., Magnavita, G., Vale, L. A. S., Mello, R. P., Nakahira, C., et al. (2018) · Medicine · doi:10.1097/md.0000000000012414 · Cited by 61 · cited 2×
“protocol for one small non-inferiority study [75] comparing single infusions of IV ketamine and IV esketamine have been published but results are not yet reported in the”
BackgroundResultTreatment-Resistant Depression: Prevalence, Risk Factors, and Treatment Strategies
Thase, M. E. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133tx4c · Cited by 60
Predictors of treatment outcome for major depression in primary care
MYNORS-WALLIS, L., & GATH, D. (1997) · Psychological Medicine · doi:10.1017/s0033291796004126 · Cited by 56 · cited 6×
“Major depressive disorder (MDD) is a common disease with a lifetime prevalence of 9.9% [1].”
BackgroundInfluentialTam, Y., Ng, C., Pang, K. K., Yee, C., Chu, W. C., Leung, V. Y., Wong, G. L., Wong, V. W., Chan, H. L., & Lai, P. B. (2014) · BJU International · doi:10.1111/bju.12675 · Cited by 54
Addictive potential of novel treatments for refractory depression and anxiety
Kolar, D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167538 · Cited by 37 · cited 1×
“It has been suggested that there is a theoretical risk for patients to develop tolerance, dependence, craving, and withdrawal related to esketamine usage [89].”
BackgroundMaintenance Ketamine Therapy for Treatment-Resistant Depression
Archer, S., Chrenek, C., & Swainson, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000894 · Cited by 34 · cited 4×
“One retrospective case series of patients with URD who had exhausted other treatment options suggested that ongoing maintenance treatments with IV ketamine may be of benefit in sustaining response in this population, although potential risks and benefits should be considered on an individual basis [23].”
BackgroundInfluentialSelf-citationAbdallah, C., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., D'Souza, D. C., Formica, R., Southwick, S. M., Duman, R. S., et al. (2018) · doi:10.1101/500959 · Cited by 30
van de Loo, A. J. A. E., Bervoets, A. C., Mooren, L., Bouwmeester, N. H., Garssen, J., Zuiker, R., van Amerongen, G., van Gerven, J., Singh, J., der Ark, P. V., et al. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4706-6 · Cited by 29 · cited 1×
“One study found that individuals who had received 84 mg of IN esketamine were not impaired on a driving safety test administered 8 h later [80].”
BackgroundUlcerative Cystitis Associated with Ketamine
Tsai, J., Tsai, K., & Jang, M. (2008) · American Journal on Addictions · doi:10.1080/10550490802266243 · Cited by 29
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Foster, K., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.02.1005 · Cited by 17
Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?
Chaki, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx120 · Cited by 17 · cited 1×
“However, more recent reports have suggested that this metabolite is not necessary for the antidepressant activity (reviewed in [42,51]).”
BackgroundEpidemiological theory, decision theory and mental health services research
Patten, S. B., & Lee, R. C. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0872-z · Cited by 11
Lee, V., Archer, S., Chrenek, C., & Swainson, J. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118822160 · Cited by 10 · cited 1×
“However, other clinical experience has found IN ketamine to be well tolerated, suggesting this could be a viable treatment option for some patients [26].”
BackgroundSelf-citationAntidepressant Efficacy and Dosing Comparisons of Ketamine Enantiomers: Response to Hashimoto
Singh, J. B., & authors, O. B. O. T. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16040411r · Cited by 5
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.289 · Cited by 5
Research works printed but not linked: 3
- Janssen Pharmaceuticals inc, 2019, SpravatoTM (esketamine hydrochloride) [Package insert]
- 10.1046/j.1440-1614.2002.01026.x · doi:10.1046/j.1440-1614.2002.01026.x
- Chu PS-K, BJU Int, 2008
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Self-citationChiral Switch: Between Therapeutical Benefit and Marketing Strategy
Hancu, G., & Modroiu, A. (2022) · Pharmaceuticals · doi:10.3390/ph15020240 · Cited by 154
Metadata
- Authors
- Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L.
- Affiliations
- University of Alberta (CA)
- Weihai City Mental Health Center (CN)
- Corresponding author
- Swainson, Jennifer
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2019-07-16
- Volume
- 19
- Issue
- 10
- Pages
- 899-911
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2959816154
- Cited by
- 151
- References
- 104
- Citations by year
- 2026: 9 · 2025: 32 · 2024: 30 · 2023: 19 · 2022: 24 · 2021: 21 · 2020: 12 · 2019: 3
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Neurotherapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- not funded
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, treatment-resistant depression, ketamine, antidepressant efficacy, drug safety, pharmacokinetics, pharmacodynamics, off-label drug use, addiction potential, long-term safety
- MeSH terms
- Antidepressive Agents, Humans, Ketamine, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.